Kowal S - Search Results

1

Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment.

Campbell DJ, Pandey R, Bloudek LM, Carlson JJ, Wallick C, Veenstra DL, Kowal S. Campbell DJ, et al. Among authors: kowal s. J Manag Care Spec Pharm. 2024 Sep;30(9):1013-1024. doi: 10.18553/jmcp.2024.30.9.1013. J Manag Care Spec Pharm. 2024. PMID: 39213143 Free PMC article.

2

Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer.

Lee W, Wong WB, Kowal S, Garrison LP Jr, Veenstra DL, Li M. Lee W, et al. Among authors: kowal s. Pharmacoeconomics. 2022 Jun;40(6):623-631. doi: 10.1007/s40273-022-01147-5. Epub 2022 May 9. Pharmacoeconomics. 2022. PMID: 35527331 Free PMC article.

3

When are breakthrough therapies cost-effective?

Olchanski N, Lin PJ, Yeh WS, Kowal S, Cohen JT. Olchanski N, et al. Among authors: kowal s. J Manag Care Spec Pharm. 2022 Jul;28(7):732-739. doi: 10.18553/jmcp.2022.28.7.732. J Manag Care Spec Pharm. 2022. PMID: 35737862 Free PMC article.

4

A Pragmatic Guide to Assessing Real Option Value for Medical Technologies.

Li M, Garrison L Jr, Lee W, Kowal S, Wong W, Veenstra D. Li M, et al. Among authors: kowal s. Value Health. 2022 Nov;25(11):1878-1884. doi: 10.1016/j.jval.2022.05.014. Epub 2022 Jun 23. Value Health. 2022. PMID: 35752536 Free article.

5

Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges.

Meunier A, Longworth L, Kowal S, Ramagopalan S, Love-Koh J, Griffin S. Meunier A, et al. Among authors: kowal s. Value Health. 2023 Jan;26(1):60-63. doi: 10.1016/j.jval.2022.06.011. Epub 2022 Aug 6. Value Health. 2023. PMID: 35941004 Free article.

6

The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals.

Synnott PG, Voehler D, Enright DE, Kowal S, Ollendorf DA. Synnott PG, et al. Among authors: kowal s. Appl Health Econ Health Policy. 2023 Mar;21(2):305-314. doi: 10.1007/s40258-022-00779-0. Epub 2022 Dec 19. Appl Health Econ Health Policy. 2023. PMID: 36529826 Review.

7

The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations.

Wong W, Kowal S, To TM, Patel A, Veenstra D, Garrison L, Li M. Wong W, et al. Among authors: kowal s. Future Oncol. 2024;20(16):1099-1110. doi: 10.2217/fon-2023-0514. Epub 2024 Jan 23. Future Oncol. 2024. PMID: 38258557 Free PMC article.

8

Does Real Option Value Influence Oncologists' Treatment Recommendations? A Survey of US Oncologists.

Li M, Elsisi Z, Wong W, Kowal S, Veenstra DL, Garrison LP Jr. Li M, et al. Among authors: kowal s. Value Health. 2024 Dec;27(12):1671-1678. doi: 10.1016/j.jval.2024.07.021. Epub 2024 Aug 9. Value Health. 2024. PMID: 39127254

9

A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States.

Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. Sheinson D, et al. Among authors: kowal s. Adv Ther. 2021 Apr;38(4):1811-1831. doi: 10.1007/s12325-021-01654-5. Epub 2021 Feb 27. Adv Ther. 2021. PMID: 33650025 Free PMC article.

10

The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis.

Kowal S, Ng CD, Schuldt R, Sheinson D, Cookson R. Kowal S, et al. Value Health. 2023 Feb;26(2):216-225. doi: 10.1016/j.jval.2022.08.010. Epub 2022 Oct 1. Value Health. 2023. PMID: 36192293 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters